Aripiprazole (Abilify®) tablets for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000411
English
Authors' recommendations:
Aripiprazole (Abilify®) is recommended as an option for use within NHS Wales for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.
Aripiprazole (Abilify®) may be suitable for shared care when used for long term treatment (i.e. prevention of manic episode) after hospital initiation.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=124168&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Bipolar Disorder
- Antipsychotic Agents
- Piperazines
- Quinolones
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.